Jump to navigation Jump to search
Mechanism of action
Diseases for which it is used
History of changes in FDA indication
- 2022-02-04: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
History of changes in EMA indication
- 2022-11-15: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
History of changes in PMDA indication
- 2022-06-20: A drug with a new active ingredient indicated for the treatment of cold agglutinin disease.
Also known as
- Code name: BIVV-009
- Generic name: sutimlimab-jome
- Brand name: Enjaymo